The Egyptian Drug Authority has released the section on medicines for the treatment of Human Immunodeficiency Virus (HIV) in the Egyptian Drug Registry 2026. This initiative is part of its ongoing efforts to develop pharmaceutical services, promote the rational use of medicines, and improve the quality of healthcare provided to patients.
This release aims to provide pharmacists and healthcare providers with accurate and comprehensive information on the optimal use of medications for the treatment of HIV, thereby enhancing the effectiveness of therapeutic practices and improving the quality of healthcare services delivered.
It also aims to improve the availability of reliable pharmaceutical information and to unify scientific references related to HIV treatment. This supports the development of pharmaceutical services, enhances the efficiency of healthcare delivery to patients, and contributes to evidence-based therapeutic decision-making to achieve optimal treatment outcomes.
The release includes the latest scientific information on medicines used in the treatment of HIV, covering the pharmacological classification of drugs, indications for use, recommended dosages and dosage adjustments, methods of administration, major drug interactions, contraindications, precautions and warnings, as well as side effects and storage guidelines. This provides a comprehensive scientific reference that supports sound pharmaceutical practice and rational therapeutic decision-making.
Source: Akhbar El-Youm Online Portal
